nach oben

Current Rheumatology Reports

Erschienen in:

01.10.2012 | SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Endoplasmic Reticulum Aminopeptidase 1 and Interleukin-23 Receptor in Ankylosing Spondylitis

verfasst von: Nigil Haroon

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Endoplasmic reticulum aminopeptidase 1 (ERAP1) and interleukin-23 receptor (IL-23R) gene polymorphisms were found to be associated with ankylosing spondylitis (AS) in a nonsynonymous single nucleotide polymorphism association study, and this has been replicated in several studies across different populations. ERAP1 variants could lead to significant changes in the repertoire of peptides presented by MHC-I. Reading this in conjunction with the known association of AS with HLA-B27, a functional interaction between ERAP1 and HLA-B27 is very likely. ERAP1 has additionally been shown to be involved in cytokine receptor shedding. The IL-23R is one of the two receptors that mediate the action of IL-23. AS is associated with the same polymorphisms of IL-23R as those linked to psoriasis and inflammatory bowel disease. This suggests common genetic risks linking AS and extra-articular manifestations. This review focuses on the pathogenic potential of these two genes in AS.

Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40:1823–8.PubMedCrossRef

Jarvinen P. Occurrence of ankylosing spondylitis in a nationwide series of twins. Arthritis Rheum. 1995;38:381–3.PubMedCrossRef

Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet. 1973;1:904–7.PubMedCrossRef

Brown MA, Laval SH, Brophy S, et al. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2000;59:883–6.PubMedCrossRef

Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet. 2001;68:918–26.PubMedCrossRef

Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329–37.PubMedCrossRef

Serwold T, Gonzalez F, Kim J, et al. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature. 2002;419:480–3.PubMedCrossRef

Saric T, Chang SC, Hattori A, et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol. 2002;3:1169–76.PubMedCrossRef

Maksymowych WP, Inman RD, Gladman DD, et al. Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis Rheum. 2009;60:1317–23.PubMedCrossRef

10.

• Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol. 2010;22:126–32. A good review of the genetics of ankylosing spondylitis. PubMedCrossRef

11.

•• Tsui FW, Haroon N, Reveille JD, et al. Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Ann Rheum Dis. 2010;69:733–6. This is the first publication to show a possible role of ERAP2 in ankylosing spondylitis. PubMedCrossRef

12.

Lee YH, Choi SJ, Ji JD, et al. Associations between ERAP1 polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Inflamm Res. 2011;60:999–1003.PubMedCrossRef

13.

Evnouchidou I, Momburg F, Papakyriakou A, et al. The internal sequence of the peptide-substrate determines its N-terminus trimming by ERAP1. PLoS One. 2008;3:e3658.PubMedCrossRef

14.

•• Kochan G, Krojer T, Harvey D, et al. Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming. Proc Natl Acad Sci U S A. 2011;108:7745–50. One of the two initial papers describing the crystal structure of ERAP1. PubMedCrossRef

15.

Nguyen TT, Chang SC, Evnouchidou I, et al. Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1. Nat Struct Mol Biol. 2011;18:604–13. One of the two initial papers describing the crystal structure of ERAP1. PubMedCrossRef

16.

Cui X, Hawari F, Alsaaty S, et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest. 2002;110:515–26.PubMed

17.

Cui X, Rouhani FN, Hawari F, et al. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol. 2003;171:6814–9.PubMed

18.

Cui X, Rouhani FN, Hawari F, et al. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem. 2003;278:28677–85.PubMedCrossRef

19.

• Haroon N, Tsui FW, Chiu B, et al. Serum cytokine receptors in ankylosing spondylitis: relationship to inflammatory markers and endoplasmic reticulum aminopeptidase polymorphisms. J Rheumatol. 2010;37:1907–10. First functional study of ERAP1 in AS showing no role for receptor shedding function in ankylosing spondylitis. PubMedCrossRef

20.

Blanchard N, Shastri N. Coping with loss of perfection in the MHC class I peptide repertoire. Curr Opin Immunol. 2008;20:82–8.PubMedCrossRef

21.

Chang SC, Momburg F, Bhutani N, et al. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci U S A. 2005;102:17107–12.PubMedCrossRef

22.

York IA, Chang SC, Saric T, et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol. 2002;3:1177–84.PubMedCrossRef

23.

Hammer GE, Gonzalez F, James E, et al. In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat Immunol. 2007;8:101–8.PubMedCrossRef

24.

••The Australo-Anglo-American Spondyloarthritis Consortium (TASC), the Wellcome Trust Case Control Consortium 2 (WTCCC2), Evans DM, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43:761–7. In this study, ERAP1 was associated with AS in only HLA-B27-positive patients and was in line with similar findings in psoriasis where a genetic interaction between ERAP1 and HLA-C was shown. PubMedCrossRef

25.

•• Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42:985–90. The first study to establish a genetic link between ERAP1 and MHC-I. ERAP1 was associated with psoriasis only in HLA-C-positive individuals. CrossRef

26.

•• Haroon N, Tsui FW, Uchanska-Ziegler B, et al. Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis. Ann Rheum Dis. 2012;71:589–95. This is the first study to establish a functional interaction between ERAP1 and HLA-B27 in AS patients. This study also showed a differential interaction between ERAP1 and HLA-B27 subtypes associated and not associated with AS. PubMedCrossRef

27.

Hattori A, Goto Y, Tsujimoto M. Exon 10 coding sequence is important for endoplasmic reticulum retention of endoplasmic reticulum aminopeptidase 1. Biol Pharm Bull. 2012;35:601–5.PubMedCrossRef

28.

Kollnberger S, Chan A, Sun MY, et al. Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol. 2007;37:1313–22.PubMedCrossRef

29.

•• Evnouchidou I, Kamal RP, Seregin SS, et al. Coding single nucleotide polymorphisms of endoplasmic reticulum aminopeptidase 1 can affect antigenic peptide generation in vitro by influencing basic enzymatic properties of the enzyme. J Immunol. 2011;186:1909–13. This study showed that ERAP1 enzymatic action follows substrate inhibition kinetics and that activity of ERAP1 can be influenced by the type and amount of substrate in the reaction. PubMedCrossRef

30.

Haroon N, Inman RD. Endoplasmic reticulum aminopeptidases: biology and pathogenic potential. Nat Rev Rheumatol. 2010;6:461–7.PubMedCrossRef

31.

Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23:613–9.PubMedCrossRef

32.

Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–7.PubMedCrossRef

33.

Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166:861–72.PubMedCrossRef

34.

• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–9. One of two studies showing the efficacy of IL-17 blockage in psoriasis. PubMedCrossRef

35.

• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9. One of two studies showing the efficacy of IL-17 blockage in psoriasis. PubMedCrossRef

36.

Cotterill L, Payne D, Levinson S, et al. Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. Can J Gastroenterol. 2010;24:297–302.PubMed

37.

Nimmo ER, Prendergast JG, Aldhous MC, et al. Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inflamm Bowel Dis. 2012;18:889–99.PubMedCrossRef

38.

•• Pidasheva S, Trifari S, Phillips A, et al. Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS One. 2011;6:e25038. Functional relevance of the IL23R association in with Crohn’s disease was shown in this study. The R381Q variant had decreased receptor function and was protective in Crohn’s disease. PubMedCrossRef

39.

Zwiers A, Kraal L, van de Pouw Kraan TC, et al. Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. J Immunol. 2012;188:1573–7.PubMedCrossRef

40.

Duan Z, Pan F, Zeng Z, et al. Interleukin-23 receptor genetic polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Rheumatol Int. 2012;32:1209–14.PubMedCrossRef

41.

DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–43.PubMedCrossRef

42.

Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum. 2011;63:3807–17.PubMedCrossRef

43.

Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60:1647–56.PubMedCrossRef

44.

Haroon N, Tsui FW, O'Shea FD, et al. From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. Ann Rheum Dis. 2010;69:297–300.PubMedCrossRef

45.

Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13:R95.PubMedCrossRef

46.

Zvyagin IV, Mamedov IZ, Britanova OV, et al. Contribution of functional KIR3DL1 to ankylosing spondylitis. Cell Mol Immunol. 2010;7:471–6.PubMedCrossRef

47.

Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC, et al. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther. 2006;8:R101.PubMedCrossRef

48.

Chan AT, Kollnberger SD, Wedderburn LR, et al. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005;52:3586–95.PubMedCrossRef

49.

•• Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186:2672–80. This study showed that KIR3DL2 receptors are important in increasing the survival and IL-17 production by NK-T cells. PubMedCrossRef

50.

Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64:1420–9.PubMedCrossRef

Titel: Endoplasmic Reticulum Aminopeptidase 1 and Interleukin-23 Receptor in Ankylosing Spondylitis
verfasst von: Nigil Haroon
Publikationsdatum: 01.10.2012
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 5/2012
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-012-0268-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Cardiovascular Disease and Rheumatoid Arthritis: An Update

Juvenile Spondyloarthropathies

Role of Ultrasound in Managing Rheumatoid Arthritis

Racial and Ethnic Disparities in Rheumatoid Arthritis

Treatment Strategies in Early Rheumatoid Arthritis and Prevention of Rheumatoid Arthritis